Episkey

Episkey is a biotechnology company focused on the discovery and development of novel small molecule therapeutics that target epigenetic mechanisms. The company leverages a proprietary platform to identify and modulate specific epigenetic regulators, such as histone-modifying enzymes, to treat complex diseases including cancer and inflammatory disorders. By focusing on the 'epigenetic code,' Episkey aims to develop precision medicines that can reprogram gene expression patterns associated with disease states. The company is currently in the pre-clinical stage, advancing a pipeline of candidates designed to address high unmet medical needs in oncology and immunology.